| pubmed-article:9383806 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9383806 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:9383806 | lifeskim:mentions | umls-concept:C0079460 | lld:lifeskim |
| pubmed-article:9383806 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:9383806 | lifeskim:mentions | umls-concept:C0027947 | lld:lifeskim |
| pubmed-article:9383806 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9383806 | pubmed:dateCreated | 1997-12-17 | lld:pubmed |
| pubmed-article:9383806 | pubmed:abstractText | Neutropenia is one of the risk factors for severe therapy-related morbidity in childhood malignancies. We have studied the potential of GM-CSF to shorten the neutropenic period after normal-dose chemotherapy in children who were treated for solid tumors. Patients with osteosarcomas, with Ewing sarcomas, or with rhabdomyosarcomas received 10 daily subcutaneous doses GM-CSF (Leucomax, 5 micrograms/kg) after a course of normal-dose chemotherapy in an open-label study. Because these patients were treated with different combinations of chemotherapeutic agents, they were randomized before each pair of identical courses of chemotherapy to receive GM-CSF after the first or after the second course. Fourteen such combinations could be evaluated in eight patients. The results show that GM-CSF significantly reduced the mean duration of the chemotherapy-induced neutropenia (mean reduction +/- SEM in days: 2.2 +/- 0.6, P = .003). There was no significant difference between the mean number of days with fever in either group. GM-CSF was well tolerated by all patients. We conclude that GM-CSF reduced the mean neutropenic period in children with solid tumors who were treated with standard-dose chemotherapy. | lld:pubmed |
| pubmed-article:9383806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9383806 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9383806 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9383806 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9383806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9383806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9383806 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9383806 | pubmed:issn | 0888-0018 | lld:pubmed |
| pubmed-article:9383806 | pubmed:author | pubmed-author:WeeninkR ORO | lld:pubmed |
| pubmed-article:9383806 | pubmed:author | pubmed-author:de CraenA JAJ | lld:pubmed |
| pubmed-article:9383806 | pubmed:author | pubmed-author:van PeltL JLJ | lld:pubmed |
| pubmed-article:9383806 | pubmed:author | pubmed-author:LangeveldN... | lld:pubmed |
| pubmed-article:9383806 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9383806 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:9383806 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9383806 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9383806 | pubmed:pagination | 539-45 | lld:pubmed |
| pubmed-article:9383806 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:meshHeading | pubmed-meshheading:9383806-... | lld:pubmed |
| pubmed-article:9383806 | pubmed:articleTitle | Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors. | lld:pubmed |
| pubmed-article:9383806 | pubmed:affiliation | Academic Medical Center, University of Amsterdam, Emma Kinderziekenhuis AMC, The Netherlands. | lld:pubmed |
| pubmed-article:9383806 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9383806 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9383806 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9383806 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9383806 | lld:pubmed |
